ArticleFrontiers in nutrition2026
CT-assessed abdominal visceral adiposity and MASLD: a sex-stratified cross-sectional analysis.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To test the hypothesis that CT-derived visceral fat and muscle measures are more strongly associated with MASLD than BMI, and that these associations are sex-specific and nonlinear, we examined abdominal body composition in relation to MASLD risk. Methods: In this cross-sectional study of 7,805 Chinese adults who underwent non-contrast abdominal CT between September 2020 and June 2023, body composition was quantified, including visceral fat area (VFA), subcutaneous fat area (SFA), skeletal muscle area (SMA), L3 skeletal muscle index (L3SMI), and CT-derived waist circumference(CT-WC). Participants were drawn from hospitalized patients undergoing CT for clinical indications ( Results: Among 7,805 participants (mean age 47.5 years; 62.2% men), MASLD prevalence was 25.8% (28.1% in men and 22.0% in women). In sex-specific fully adjusted models, VFA showed the strongest and most consistent association with MASLD. Men in the highest VFA quartile had an odds ratio (OR) of 11.5 (95% CI 8.3-16.1) compared with the lowest quartile, while women exhibited a markedly steeper risk gradient (OR 32.5, 95% CI 17.3-67.0). Waist circumference (WC) showed similar independent associations, whereas BMI was not independently associated with MASLD in men but remained significant in women. Subcutaneous fat and skeletal muscle measures were weakly associated or not significant after adjustment. Restricted cubic spline analyses revealed pronounced nonlinear and threshold effects for visceral fat, with risk rising sharply beyond sex-specific VFA thresholds. CT-derived body composition models improved MASLD discrimination compared with BMI alone (AUC 0.76 vs. 0.70 in men; 0.83 vs. 0.77 in women). Associations were consistent across metabolic subgroups and robust to sensitivity analyses, including E-value assessment for unmeasured confounding. Conclusion: CT-based measures of visceral fat may provide significant incremental value over BMI in MASLD risk assessment. Findings suggest that MASLD risk may differ by sex and appears to be more closely related to fat distribution than to total adiposity, highlighting the potential need to incorporate central obesity assessment into clinical and public health strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.